НовостиBenzingaRBC Capital Maintains Outperform on Versigent, Raises Price Target to $53 RBC Capital Maintains Outperform on Versigent, Raises Price Target to $53 Benzinga 2026.10.12 14:19 (GMT+0) Открыть на Benzinga Другие новости